Although aminotransferase (ALT) and viral nucleic acid levels are used to predict prognosis in CHB patients, neither is considered sensitive enough to guide antiviral treatment per se, as there is a considerable volume of patients with hepatic necroinflammation and severe hepatic fibrosis with neither detectable HBV DNA nor elevated ALT levels [8]. This evidence concerns the gene GPT and Hepatic fibrosis.